From NAFLD to MASLD – a new approach for the definition of fatty liver disease associated with metabolic dysfunction
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common, affecting a quarter of the population. The pathogenesis of this disease is multifactorial and has been well known for years. After 40 years of using the binding definition of non-alcoholic fatty liver disease (NAFLD), in 202...
| Published in: | Studia Medyczne |
|---|---|
| Main Authors: | Iwona Gorczyca-Głowacka, Łukasz Nawacki, Magdalena Dolecka-Ślusarczyk, Agnieszka Ciba-Stemplewska, Stanisław Głuszek |
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2025-01-01
|
| Subjects: | |
| Online Access: | https://www.termedia.pl/From-NAFLD-to-MASLD-a-new-approach-for-the-definition-of-fatty-liver-disease-associated-with-metabolic-dysfunction,67,55301,1,1.html |
Similar Items
Vitamin D deficiency as a risk factor for metabolic dysfunction-associated steatotic liver disease
by: Agnieszka Ciba-Stemplewska, et al.
Published: (2025-01-01)
by: Agnieszka Ciba-Stemplewska, et al.
Published: (2025-01-01)
Sex-related differences in the prevalence, clinical characteristics, and comorbidities of metabolic dysfunction-associated steatotic liver disease
by: Agnieszka Ciba-Stemplewska, et al.
Published: (2025-09-01)
by: Agnieszka Ciba-Stemplewska, et al.
Published: (2025-09-01)
Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review
by: Emilia Kowalczyk, et al.
Published: (2025-09-01)
by: Emilia Kowalczyk, et al.
Published: (2025-09-01)
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
by: Shuhei Fukunaga, et al.
Published: (2024-01-01)
by: Shuhei Fukunaga, et al.
Published: (2024-01-01)
Can We Predict the Insulin Therapy Need and Early Postpartum Prediabetes in Patients with Gestational Diabetes Mellitus?
by: Magdalena Dolecka-Ślusarczyk, et al.
Published: (2023-08-01)
by: Magdalena Dolecka-Ślusarczyk, et al.
Published: (2023-08-01)
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
by: Hiroyuki Suzuki, et al.
Published: (2024-07-01)
by: Hiroyuki Suzuki, et al.
Published: (2024-07-01)
From NAFLD to MASLD: When metabolic comorbidity matters
by: Shan Hong, et al.
Published: (2024-03-01)
by: Shan Hong, et al.
Published: (2024-03-01)
Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Thaninee Prasoppokakorn
Published: (2025-01-01)
by: Thaninee Prasoppokakorn
Published: (2025-01-01)
NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options
by: Natalia G. Vallianou, et al.
Published: (2024-06-01)
by: Natalia G. Vallianou, et al.
Published: (2024-06-01)
Secondary prevention of thromboembolic complications in patients with nonvalvular atrial fibrillation – clinical practice in relation to guidelines
by: Bernadetta Bielecka, et al.
Published: (2023-06-01)
by: Bernadetta Bielecka, et al.
Published: (2023-06-01)
Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)
by: Mubin Ozercan, et al.
Published: (2025-01-01)
ASSOCIATION BETWEEN ANXIETY AND DEPRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
by: Eloyse Cristina BOTACIN, et al.
Published: (2024-07-01)
by: Eloyse Cristina BOTACIN, et al.
Published: (2024-07-01)
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Soyeon Shin, et al.
Published: (2023-12-01)
by: Soyeon Shin, et al.
Published: (2023-12-01)
Liver Stiffness, Not Steatosis, Predicts Mortality in MASLD Patients: An NHANES Analysis
by: Yuting Huang, et al.
Published: (2024-12-01)
by: Yuting Huang, et al.
Published: (2024-12-01)
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
by: Carole Vitellius, et al.
Published: (2024-10-01)
by: Carole Vitellius, et al.
Published: (2024-10-01)
Helicobacter pylori infection and association with chronic diseases: A focus on cardiovascular disease, MASLD, and type 2 diabetes
by: Navid Maleki, et al.
Published: (2025-09-01)
by: Navid Maleki, et al.
Published: (2025-09-01)
Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis
by: Nazanin Hosseinkhan, et al.
Published: (2025-05-01)
by: Nazanin Hosseinkhan, et al.
Published: (2025-05-01)
Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Julia Markowska, et al.
Published: (2024-11-01)
by: Julia Markowska, et al.
Published: (2024-11-01)
From NAFLD to MASLD: Promise and pitfalls of a new definition
by: Kenneth Cusi, et al.
Published: (2024-07-01)
by: Kenneth Cusi, et al.
Published: (2024-07-01)
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Amani Elshaer, et al.
Published: (2024-07-01)
by: Amani Elshaer, et al.
Published: (2024-07-01)
Development and pilot evaluation of an evidence-based algorithm for MASLD (formerly NAFLD) management in primary care in Europe
by: Marilena Anastasaki, et al.
Published: (2024-11-01)
by: Marilena Anastasaki, et al.
Published: (2024-11-01)
Effect of a Ketogenic Diet on Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)
Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review
by: Francisco Aguirre, et al.
Published: (2025-07-01)
by: Francisco Aguirre, et al.
Published: (2025-07-01)
Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden
by: Maha Elsabaawy, et al.
Published: (2025-09-01)
by: Maha Elsabaawy, et al.
Published: (2025-09-01)
Common Denominator of MASLD and Some Non-Communicable Diseases
by: Katarzyna Ferenc, et al.
Published: (2024-06-01)
by: Katarzyna Ferenc, et al.
Published: (2024-06-01)
Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review
by: Katharina Burger, et al.
Published: (2025-06-01)
by: Katharina Burger, et al.
Published: (2025-06-01)
Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition’
by: Mary E. Rinella, et al.
Published: (2024-07-01)
by: Mary E. Rinella, et al.
Published: (2024-07-01)
Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) from a Young Age Due to a Rare Genetic Disorder, Familial Partial Lipodystrophy: A Case Report and Review of the Literature
by: Elena Vorona, et al.
Published: (2024-12-01)
by: Elena Vorona, et al.
Published: (2024-12-01)
Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
by: Toru Nakamura, et al.
Published: (2025-03-01)
by: Toru Nakamura, et al.
Published: (2025-03-01)
Predictive factors for metabolic syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
by: Mohammad Alnees, et al.
Published: (2025-08-01)
by: Mohammad Alnees, et al.
Published: (2025-08-01)
Autoantibodies are associated with worse outcomes in MASLD
by: Anna Soria, et al.
Published: (2025-10-01)
by: Anna Soria, et al.
Published: (2025-10-01)
The burden of NAFLD (now referred to as MASLD)-related chronic liver disease and cirrhosis from 1990 to 2021 with projections to 2036: a comparative study of global China the United States and India
by: Juanjuan Zeng, et al.
Published: (2025-09-01)
by: Juanjuan Zeng, et al.
Published: (2025-09-01)
Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)
Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD
by: Daniela Gabbia, et al.
Published: (2023-11-01)
by: Daniela Gabbia, et al.
Published: (2023-11-01)
Targeting duodenum to reverse MASLD
by: Amedeo Lonardo, et al.
Published: (2025-06-01)
by: Amedeo Lonardo, et al.
Published: (2025-06-01)
The association between cardiometabolic index (CMI) and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
by: Alireza Azarboo, et al.
Published: (2025-08-01)
by: Alireza Azarboo, et al.
Published: (2025-08-01)
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
by: Joo Hyun Oh, et al.
Published: (2024-04-01)
by: Joo Hyun Oh, et al.
Published: (2024-04-01)
Identification of pediatric MASLD using insulin resistance indices
by: Kyungchul Song, et al.
Published: (2025-07-01)
by: Kyungchul Song, et al.
Published: (2025-07-01)
Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
by: Umasankari S., et al.
Published: (2024-12-01)
by: Umasankari S., et al.
Published: (2024-12-01)
Cognitive Impairment in MASLD is associated with Amygdala-Related Connectivity Dysfunction in the Prefrontal and Sensory Cortex
by: Yihan Jin, et al.
Published: (2024-12-01)
by: Yihan Jin, et al.
Published: (2024-12-01)
Similar Items
-
Vitamin D deficiency as a risk factor for metabolic dysfunction-associated steatotic liver disease
by: Agnieszka Ciba-Stemplewska, et al.
Published: (2025-01-01) -
Sex-related differences in the prevalence, clinical characteristics, and comorbidities of metabolic dysfunction-associated steatotic liver disease
by: Agnieszka Ciba-Stemplewska, et al.
Published: (2025-09-01) -
Impact of Various Oral Hypoglycemic Agents on Hepatic Steatosis Reduction in MASLD and Type 2 Diabetes: Exploring the Bidirectional Relationship. A Narrative Review
by: Emilia Kowalczyk, et al.
Published: (2025-09-01) -
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
by: Shuhei Fukunaga, et al.
Published: (2024-01-01) -
Can We Predict the Insulin Therapy Need and Early Postpartum Prediabetes in Patients with Gestational Diabetes Mellitus?
by: Magdalena Dolecka-Ślusarczyk, et al.
Published: (2023-08-01)
